While a large proportion of patients presenting with stage I and II squamous cell carcinoma
of the head and neck (SCCHN) will remain disease free after single modality treatment, the …

Taxanes, mainly paclitaxel and docetaxel, the microtubule stabilizers, have been well known
for being the first-line therapy for breast cancer for more than the last thirty years. Moreover …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

Therapeutic management of locally advanced, recurrent and metastatic head and neck
squamous cell carcinoma (HNSCC) is often limited by a rather unfavorable efficacy and …

Conclusions. Weekly paclitaxel may be an active and well tolerated chemotherapy regimen
for patients with platin-resistant advanced head and neck cancer. Objectives. Weekly …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

OBJECTIVE: Worldwide, head and neck carcinomas account for 5% of all malignancies.
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Importance of the field: Head and neck cancer is the sixth most common cancer worldwide.
Despite intense efforts to improve different treatment modalities, mortality rates in advanced …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …